Skip to main content

Table 2 Comparison of major morbidities and biochemical parameters between SLE group and non-SLE group

From: Association of preterm outcome with maternal systemic lupus erythematosus: a retrospective cohort study

Variables

SLE group

Non-SLE group

Total

P value

Number

98

196

294

 

Gestational age(weeks)

33.13 ± 2.06

33.15 ± 2.17

33.14 ± 2.13

0.925

Birth weight(g)

1769.69 ± 423.94

1811.46 ± 408.90

1797.54 ± 413.72

0.415

SGA

36 (36.7%)

52 (26.5%)

88(29.9%)

0.072

Cesarean section

90 (91.8%)

154 (78.5%)

244(83.0%)

0.004**

1 min Apgar ≤ 7

11(11.2%)

39 (19.9%)

50(17.0%)

0.062

5 min Apgar ≤ 7

1(1.0%)

10(5.6%)

11(3.7%)

0.082

Morbidity

    

BPD

15(15.3%)

41(20.9%)

56(19%)

0.250

IVH/PVL

0(0%)

2(1.0%)

2(0.7%)

0.997

ROP

1(1.0%)

0(0%)

1(0.3%)

0.995

NEC

2(2.0%)

7(3.6%)

9(3.1%)

0.478

Sepsis

0(0%)

5(2.6%)

5(1.7%)

0.997

Survival without major mobidites

82(83.7%)

147(75%)

229(77.9%)

0.093

Congenital heart disease#

50(71.4%)

96(73.8%)

146(73.0%)

0.713

Biochemical parameters

    

Day one

    

Leukocyte(*10^9/L)

9.47 ± 4.69

12.18 ± 7.20

11.28 ± 6.59

0.001**

Neutrophile(*10^9/L)

4.55 ± 2.61

6.44 ± 3.94

5.82 ± 3.66

0.000**

Platlet(*10^9/L)

226.70 ± 77.29

224.52 ± 76.31

225.25 ± 76.51

0.818

Hemoglobin(g/L)

173.20 ± 23.08

171.98 ± 28.92

172.39 ± 27.08

0.715

One week

    

Leukocyte(*10^9/L)

10.08 ± 3.46

12.16 ± 13.45

11.47 ± 11.20

0.133

Neutrophile(*10^9/L)

3.97 ± 2.13

4.74 ± 3.19

4.48 ± 2.90

0.014*

Platlet(*10^9/L)

221.14 ± 99.24

265.15 ± 110.55

250.48 ± 108.75

0.001**

Hemoglobin(g/L)

161.75 ± 34.43

159.70 ± 39.57

160.38 ± 37.88

0.663

Lowest Hemoglobin(g/L)

126.16 ± 34.15

118.72 ± 33.54

121.20 ± 33.87

0.076

Lowest Platlet(*10^9/L)

172.42 ± 81.01

177.23 ± 79.08

175.63 ± 79.62

0.626

TBil max(U/L)

146.38 ± 47.35

139.70 ± 55.27

141.93 ± 52.77

0.307

ALT max(umol/L)

21.94 ± 37.79

20.66 ± 31.67

21.08 ± 33.77

0.759

  1. #In our clinical practice, we only condut echocardiography examination on the neonates with positive CHD screening
  2. *P<0.05, **P<0.01